RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
Paying $3.3bn
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.
